Clinical trials: Allogenic Stem Cell Transplantation, open to volunteers
Acute Myeloid Leukemia, Graft Versus Host Disease
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute…
- Conditions
- Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
- Trial name
- NCT06996119
- Testing
- Biospecimen Collection, Busulfan, Computed Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Acute Graft-versus-Host Disease
A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
An open-label, randomized, controlled clinical trial to explore the efficacy and safety of iMSC in preventing the development of acute graft-versus-host disease of degree III-IV in patients after allogeneic hematopoietic stem…
- Trial name
- NCT06949267
- Testing
- iMSC, conventional aGVHD prophylaxis
- Volunteers
- 56 people
- Sponsor
- Ruijin Hospital
T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients.
- Trial name
- RRTCLAlloSCT (NCT02859402)
- Testing
- Busulfan, Fludarabine
- Where
- 2 sites in South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Keimyung University Dongsan Medical Center
Transplant-Related Disorder
daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT
This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.
- Trial name
- NCT07588945
- Testing
- Ruxolitinib
- Volunteers
- 438 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid)
Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
A first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation…
- Conditions
- Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic
- Trial name
- ThINKK-01 (NCT07518654)
- Testing
- Therapeutic Inducers of Natural Killer Killing (ThINKK)
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Michel Duval
Acute Leukemia, Acute Lymphoblastic Lymphoma
Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow…
- Trial name
- NCT06803745
- Testing
- 200 cGy or 400 cGy total body irradiation (TBI)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
- Trial name
- NCT06704542
- Where
- 6 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort.
- Trial name
- NCT06529731
- Testing
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sawa Ito, MD
Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis…
- Trial name
- PTCYGVHD (NCT06799195)
- Testing
- Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Nebraska
Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance
Allogeneic hematopoietic stem cell transplantation (alloHSCT) showed efficacy in advanced-stage, high-risk, treatment sensitive cutaneous T-cell lymphomas (CTCL) in a prospective, propensity score-matched controlled study…
- Trial name
- BeCALM (NCT07178457)
- Testing
- Brentuximab Vedotin (Bv)
- Volunteers
- 84 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation
The goal of this clinical trial is to evaluate whether a virtual reality (VR) intervention based on the Symptom Management Model can reduce physical and psychosocial symptoms during hematopoietic stem cell transplantation (HSCT)…
- Conditions
- Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Nursing Interventions, Symptom Management
- Trial name
- NCT07145359
- Testing
- Virtual Reality Intervention
- Volunteers
- 30 people
- Sponsor
- Halic University
AML (Acute Myelogenous Leukemia)
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia after allogeneic hematopoietic stem cell…
- Trial name
- NCT06783790
- Testing
- Avapritinib, azacitidine, Venetoclax
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Myelodysplastic Syndromes, Myeloid Leukemia, Acute
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety/tolerability of TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in…
- Trial name
- TMLI-MA (NCT06598969)
- Testing
- Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Background: Stem cell transplants from related donors (allogenic stem cell transplants) can be used to treat individuals with certain kinds of severe blood diseases or cancers, such as severe anemia.
- Trial name
- NCT01174108
- Testing
- Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease
Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy
An open-label, single-arm clinical trial to evaluate the safety and efficacy of gecacitinib tablets in patients with acute graft-versus-host disease (GVHD) who have failed or are intolerant to ruxolitinib-containing second-line…
- Trial name
- GRIT (NCT07197112)
- Testing
- Gecacitinib
- Volunteers
- 15 people
- Sponsor
- Ruijin Hospital
Hematopoietic Stem Cell Transplantation
Employment Support After Hematopoietic Stem Cell Transplantation
This is a feasibility study of a Work Support (WorkS) intervention designed to ameliorate employment challenges for people preparing to return to work after allogeneic stem cell transplantation.
- Trial name
- WorkS (NCT06494423)
- Testing
- Work Support (WorkS)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- MGH Institute of Health Professions
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT).
- Trial name
- NCT03127761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplant
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Stem Cell Transplant Complications, Acute Graft Versus Host Disease
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region.
- Conditions
- Stem Cell Transplant Complications, Acute Graft Versus Host Disease, Acute Kidney Injury, Major Adverse Cardiac Events
- Trial name
- NCT06386445
- Testing
- Serum metabolomics sequencing
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University